Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of anlotinib plus docetaxel as second-line therapy for advanced non-small cell lung cancer
ChiCTR1800020011Phase 2Completed
- Sponsor
- Hangzhou First People's Hospital
- Start
- Nov 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and docetaxel in non-small cell lung cancer (NSCLC), sponsored by Hangzhou First People's Hospital. Primary endpoints: Objective response rate and Overall survival. Started Nov 2018; status: completed.
02
Drugs
anlotinibdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1800020011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800020011.